Research suggests- Concurrent therapy not necessary to achieve high pathological in breast cancer

It is much believed that if a patient is given trastuzumab and anthracyclines together it can effectively treat HER-2-positive breast cancer, but they are not very sure about the after effects of it. A new research conducted at The University of Texas have further went deep into it and found that these drugs do not need to be given parallel to achieve a high rate of complete pathological reduction otherwise it may lead to adverse side effects. It should be either given one by one or with some gap between it. This detailed report is published in the journal Lancet Oncology. The lead researcher, Aman Buzdar M.D., professor and vice president of clinical research at The University of Texas MD Anderson Cancer Center explains, “In a previous MD Anderson study concurrent administration of trastuzumab with chemotherapy, including anthracyclines, demonstrated high pathologic complete response rates in breast cancer patients with HER-2-positive disease.”